Lin Wei-De, Ke Yu-Yuan, Chou I-Ching, Wang Chung-Hsing, Tsai Fuu-Jen
Department of Medical Research, China Medical University Hospital, Taichung; 2.School of Post Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan.
Tohoku J Exp Med. 2015 Apr;235(4):267-73. doi: 10.1620/tjem.235.267.
Mucopolysaccharidosis type VI (MPS VI) is a rare autosomal recessive disorder caused by a deficiency of N-acetylgalactosamine-4-sulfatase (ARSB), one of the enzymes required for the degradation of dermatan sulfate (DS). Accumulation of DS in connective tissue causes growth failure, resulting in short stature. Here, we observed a 5-year-old girl who was the only one affected member of her family and who presented with an exaggerated, convex curvature of the back at the age of one year. Abnormal excretion of DS in the urine and extremely low leukocyte ARSB activity were noted. The patient was suspected to have MPS VI. Direct DNA sequencing indicated that there was no mutation in the coding region of ARSB. However, RT-PCR analysis of RNA prepared from blood samples indicated the deletion of the entire exon 4. Further analysis of the genomic DNA by quantitative PCR confirmed a homozygous deletion of exon 4, an unusual intragenic deletion in ARSB. The deletion led to a truncated protein that lacks most of the catalytic domain. The patient received recombinant human ARSB as enzyme replacement therapy (ERT) at an early stage (2 years), and responded positively in terms of skeletal development and other developmental milestones. The early identification of type VI MPS patients and subsequent treatment with ERT may be beneficial for the clinical outcome of MPS VI patients. In addition, detailed gene analysis may enhance the ability to provide genetic counseling to families of patients affected by MPS VI.
黏多糖贮积症 VI 型(MPS VI)是一种罕见的常染色体隐性疾病,由 N - 乙酰半乳糖胺 - 4 - 硫酸酯酶(ARSB)缺乏引起,ARSB 是硫酸皮肤素(DS)降解所需的酶之一。DS 在结缔组织中的蓄积导致生长发育迟缓,进而造成身材矮小。在此,我们观察到一名 5 岁女孩,她是家族中唯一患病成员,1 岁时即出现背部过度的、凸起的弯曲。尿液中 DS 排泄异常,白细胞 ARSB 活性极低。该患者被怀疑患有 MPS VI。直接 DNA 测序表明 ARSB 编码区无突变。然而,对血液样本制备的 RNA 进行 RT - PCR 分析显示整个外显子 4 缺失。通过定量 PCR 对基因组 DNA 进行进一步分析证实外显子 4 纯合缺失,这是 ARSB 中一种不寻常的基因内缺失。该缺失导致一种截短的蛋白质,其缺乏大部分催化结构域。患者在早期(2 岁)接受了重组人 ARSB 作为酶替代疗法(ERT),在骨骼发育和其他发育里程碑方面有积极反应。早期识别 VI 型 MPS 患者并随后进行 ERT 治疗可能对 MPS VI 患者的临床结局有益。此外,详细的基因分析可能增强为受 MPS VI 影响患者的家庭提供遗传咨询的能力。